RxDoctor Payments Data

Syed Asad, MD

Neurology · Jacksonville, FLNPI 1497851042

Payments from drug & device makers

$310,125in general payments, 2019–2025

Across 2,148 payments — averaging $144.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$170K
  • Otsuka America Pharmaceutical, Inc.$32K
  • AbbVie$26K
  • Biohaven Pharmaceuticals, Inc.$25K
  • Jazz Pharmaceuticals Inc.$11K
  • Eli Lilly$8K
  • plus $39K from 54 others

What the payments were for

  • Consulting fees$30,45610%
  • Speaking & faculty fees$210,08870%
  • Travel & lodging$26,1179%
  • Food & beverage$34,87812%
  • Education$7130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Avanir Pharmaceuticals, Inc.261$169,552
Otsuka America Pharmaceutical, Inc.60$32,444
AbbVie(2 entities)371$25,614
Biohaven Pharmaceuticals, Inc.64$24,576
Jazz Pharmaceuticals Inc.40$10,808
Eli Lilly5$7,874
Novartis109$7,709
Biohaven Pharmaceutical Holding Company Ltd.21$5,359
Amgen98$2,569
Argenx US, Inc.14$2,542
Teva Pharmaceuticals USA, Inc.151$1,685
EMD Serono, Inc.102$1,332
Medtronic(2 entities)18$1,278
Abbott12$1,260
Supernus Pharmaceuticals, Inc.23$1,249
Lundbeck LLC82$1,018
Lilly USA, LLC59$1,007
Biogen60$887
Eisai Inc.51$832
Pfizer45$744
AstraZeneca31$739
Genentech USA, Inc.33$663
CSL Behring31$652
UCB, Inc.20$500
Kyowa Kirin, Inc.34$490
MDD US Operations, LLC29$453
Boston Scientific11$439
Sanofi24$427
Acadia Pharmaceuticals Inc21$368
Adamas Pharmaceuticals, Inc.24$367
Upsher-smith Laboratories LLC20$320
Neurocrine Biosciences, Inc.14$264
Neuronetics, Inc.4$254
Neurelis, Inc.14$252
TG Therapeutics, Inc.7$235
Axsome Therapeutics, Inc.6$222
Johnson & Johnson(2 entities)11$217
Takeda Pharmaceuticals U.S.A., Inc.8$189
Bristol Myers Squibb10$187
Vanda Pharmaceuticals Inc.8$174
Corium, LLC9$154
Livanova USA, Inc.10$154
Promius Pharma LLC15$130
Zyla Life Sciences, Inc.9$123
E.r. Squibb & Sons, L.L.C.3$111
Assertio Therapeutics, Inc.12$110
Mallinckrodt Hospital Products Inc.6$102
Greenwich Biosciences, Inc.6$101
Almatica Pharma LLC6$93
SK Life Science, Inc.4$90
Tersera Therapeutics LLC4$88
Grifols USA, LLC5$83
Bausch Health US, LLC4$79
Merz Pharmaceuticals, LLC4$78
Catalyst Pharmaceuticals, Inc.3$78
Arbor Pharmaceuticals, Inc.5$73
Tanabe Pharma America, Inc.4$71
Acorda Therapeutics, Inc4$71
Mallinckrodt Enterprises LLC3$63
Merz North America, Inc.3$54

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$310,125 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$382,954
Medicare patients
632
Services billed
18,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyclarysOmaveloxolone12$374,782
PanzygaImmun Glob G(Igg)-Ifas/Glycine32$359,490
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$291,502
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$248,420
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$124,411
BotoxOnabotulinumtoxina45$59,643
NuedextaDextromethorphan Hbr/Quinidine31$50,544
QuviviqDaridorexant Hcl38$18,022
BelsomraSuvorexant36$17,349
Emgality PenGalcanezumab-Gnlm12$8,145
Rivastigmine23$4,479
DayvigoLemborexant13$4,081
Ramelteon19$3,603
Lacosamide43$3,192
Pregabalin89$2,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Octagam$744$650,99245 claims
BiogenSkyclarys$887$374,78212 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$189$248,42020 claims
Grifols USA, LLCGamunex-C$83$124,41113 claims
AbbVieBotox$25,614$59,64345 claims
Avanir Pharmaceuticals, Inc.Nuedexta$169,552$50,54431 claims
Eisai Inc.Dayvigo$832$4,08113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →